Participated · Series A · Apr 2026

Hypervision Surgical is a London-based medical technology company and a King's College London spin-out led by CEO Michael Ebner. It develops a platform that integrates proprietary spectral sensing with patented AI analytics to provide quantitative tissue insights during surgery. The company aims to integrate its hyperspectral imaging solution into laparoscopic, robotic, microscopic and endoscopic surgical platforms. The announced Series A will support expansion of operations and continued R&D. The article does not disclose revenue, user metrics, or prior financing rounds.

Led · Equity · Feb 2026

Pharmacelera deploys its proprietary 3-D Quantum Mechanics and Artificial Intelligence engine, branded QaiM, to search the chemical “exaSpace” of trillions of molecules with high speed and accuracy. The platform can deliver drug candidates up to ten times better and 75,000 times faster than traditional AI-led discovery methods, and is applicable from hit identification through lead optimization. To date the company’s cross-disciplinary team has executed more than 100 discovery projects and secured repeat business from three large pharmaceutical companies as well as numerous biotech clients. Pharmacelera operates from Parc Científic de Barcelona, one of Europe’s key life-science hubs, and maintains a diversified, scalable service model. The firm formed a strategic alliance in 2023 with Silicon Valley “igniter” General Inception, becoming that group’s AI drug-discovery partner and strengthening IP for several GI portfolio companies. Current plans include establishing a permanent U.S. team to deepen relationships with biopharma customers on both coasts and expanding the technical capabilities of the QaiM engine. Although revenue figures were not disclosed, the repeat engagements with big pharma and over a hundred completed projects indicate growing commercial traction.

Led · Seed · Apr 2025

Nuclivision is a Ghent-based medtech founded in 2022 that develops Nuclarity, an AI software platform to enhance PET imaging. Nuclarity aims to shorten scan times and lower required radiotracer doses while preserving image quality. The company targets PET use cases in cancer and Alzheimer’s diagnosis and treatment planning. Nuclivision is in the final phase of regulatory approval and plans a European commercial launch with a U.S. entry expected later this year. The business recently secured external funding to support the commercial rollout of its flagship product. The company is presented as part of a broader wave of European deeptech startups applying AI to complex healthcare procedures. Nuclivision offers an AI-driven imaging platform that automates the identification of symptoms on PET readouts, enabling faster diagnoses without undermining accuracy. The company targets nuclear medicine workflows to reduce costs and lower radioactive exposure for patients and staff. It was founded last June by Gregor Strobbe, Nikos Paragios, Jean-Briac Prévost, Alex Maes, Roland Hustinx, Stefaan Vandenberghe and Dr. Sezgin Üstmert. Nuclivision is based in Ghent. The startup disclosed a fundraising from Ghent VC Luminaires and says it expects to have sufficient runway to refine its PET product. The articles highlight the company’s mission to make nuclear imaging and therapies more accessible and more cost-effective.

Participated · Series A · Sep 2023

Broken String Biosciences is a Cambridge-based genomics company developing INDUCE-seq, an NGS-based DNA break mapping platform aimed at making cell and gene therapies safer by design. INDUCE-seq leverages a PCR-free approach to directly measure and quantify DNA double-strand breaks and assess off-target editing events for genome editing tools such as CRISPR-Cas9. The platform provides data-driven, actionable insights across discovery, pre-clinical and clinical development to inform therapeutic programs and mitigate later-stage risks. The $15M Series A will be used to develop INDUCE-seq into a scalable Platform-as-a-Service (PaaS), expand capabilities beyond gene editing, broaden the company’s go-to-market strategy, and drive commercial traction. Funding will also support recruitment for the UK team at the Wellcome Genome Campus and the establishment of a US office. The company has demonstrated progress since its 2021 seed round and, according to investors, has generated repeat revenues across a portfolio of partners.

Led · Equity · Sep 2023

Thirona, founded in 2014 by Eva van Rikxoort and based in Nijmegen, Netherlands, develops high-precision AI analysis for thoracic CT images. It offers expertise-based services and AI-powered lung image analysis to MedTech, pharmaceutical, and CRO companies. Thirona partners with research institutions and medical companies on innovation programs aimed at enabling breakthroughs in precision medicine for pulmonary diseases. The company’s stated mission is to apply domain knowledge and artificial intelligence to make personalized treatments for lung diseases more accessible. Thirona recently secured €7.5M in funding to support efforts to advance precision medicine and enhance patient care for lung diseases. Its software category is AI-powered medical image analysis and its website is thirona.eu. Thirona builds computer algorithms for medical image analysis, concentrating on lung CT scans. The company is a Radboud University medical spin-off founded in 2014 by Eva van Rikxoort and Bram van Ginneken. Its work aims to improve diagnostic speed and accuracy and to reduce physicians' workload through AI-assisted image analysis. Thirona is participating in collaborative projects to extend its algorithm development into oncology imaging. The company is working alongside clinical and industry partners to integrate imaging into precision‑medicine workflows. The article does not disclose revenue, users, or other financial metrics.